The FDA has accepted a new supplemental Biologics License Application and granted Priority Review for Merck's pembrolizumab (Keytruda) for the treatment of advanced cervical cancer, marking the first filing acceptance for an anti–PD-1 therapy in cervical cancer.
The FDA has accepted a new supplemental Biologics License Application and granted Priority Review for pembrolizumab (Keytruda) for the treatment of advanced cervical cancer, announced Merck in a press release.
According to Merck, this marks the first filing acceptance and Priority Review granted for an anti—PD-1 therapy in cervical cancer and the 14th regulatory submission accepted by the FDA for pembrolizumab.
“Advanced cervical cancer is an illness with a poor prognosis and a high unmet medical need,” said Roger Dansey, MD, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories, in a statement. “We look forward to working with the FDA on the review of this application to help bring Keytruda to previously-treated patients with advanced cervical cancer.”
The application is seeking approval for pembrolizumab as treatment for patients with advanced cervical cancer with disease progression on or after chemotherapy and is based in part on data from the phase 2 KEYNOTE-158 trial. The ongoing global, open-label, non-randomized, multi-cohort, multi-center trial is evaluating pembrolizumab in patients with multiple types of solid tumors, including cervical cancer.
Pembrolizumab currently has indications for certain types of melanoma, non—small-cell lung cancer, head and neck cancer, classical Hodgkin lymphoma, urothelial cancer, microsatellite instability-high cancer, and gastric cancer.
Study findings presented at ASCO’s 2018 Genitourinary Cancers Symposium last month showed that there is greater overall survival benefit with recurrent urothelial cancer being treated with pembrolizumab versus chemotherapy. According to Joaquim Bellmunt, MD, PhD, of the Dana Farber Institute, this is the first immunotherapy to demonstrate superior survival over chemotherapy in patients with advanced urothelial carcinoma after failure of platinum-based therapy.
In January, Merck announced that the FDA had granted a Breakthrough Therapy Designation for lenvatinib and pembrolizumab as combination therapy for advanced and/or metastatic renal cell carcinoma (RCC) based on results from the RCC cohort in Study 111, which evaluated the safety and efficacy of the combination in selected solid tumors.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More